509 related articles for article (PubMed ID: 30413822)
1. High-Grade Dysplasia in Resected Main-Duct Intraductal Papillary Mucinous Neoplasm (MD-IPMN) is Associated with an Increased Risk of Subsequent Pancreatic Cancer.
Majumder S; Philip NA; Singh Nagpal SJ; Takahashi N; Mara KC; Kendrick ML; Smyrk TC; Zhang L; Levy MJ; Gleeson FC; Petersen BT; Pearson RK; Topazian MD; Vege SS; Chari ST
Am J Gastroenterol; 2019 Mar; 114(3):524-529. PubMed ID: 30413822
[TBL] [Abstract][Full Text] [Related]
2. MUC2 expression and prevalence of high-grade dysplasia and invasive carcinoma in mixed-type intraductal papillary mucinous neoplasm of the pancreas.
Masuda A; Arisaka Y; Hara S; Matsumoto I; Takenaka M; Sakai A; Shiomi H; Matsuki N; Sugimoto M; Fujita T; Hayakumo T; Ku Y; Ogino S; Azuma T; Kutsumi H
Pancreatology; 2013; 13(6):583-8. PubMed ID: 24280573
[TBL] [Abstract][Full Text] [Related]
3. Segmental Versus Diffuse Main Duct Intraductal Papillary Mucinous Neoplasm: Examination of Main Pancreatic Duct Morphology and Implications for Malignancy Risk and Extent of Surgical Resection.
Ecker BL; Dickinson SM; Saadat LV; Tao AJ; Pulvirenti A; Balachandran VP; D'Angelica MI; Drebin JA; Kingham TP; Jarnagin WR; Wei AC; Gonen M; Soares KC
Ann Surg; 2023 Jul; 278(1):110-117. PubMed ID: 35950775
[TBL] [Abstract][Full Text] [Related]
4. Long-term Risk of Malignancy in Branch-Duct Intraductal Papillary Mucinous Neoplasms.
Oyama H; Tada M; Takagi K; Tateishi K; Hamada T; Nakai Y; Hakuta R; Ijichi H; Ishigaki K; Kanai S; Kogure H; Mizuno S; Saito K; Saito T; Sato T; Suzuki T; Takahara N; Morishita Y; Arita J; Hasegawa K; Tanaka M; Fukayama M; Koike K
Gastroenterology; 2020 Jan; 158(1):226-237.e5. PubMed ID: 31473224
[TBL] [Abstract][Full Text] [Related]
5. Invasive, mixed-type intraductal papillary mucinous neoplasm: superior prognosis compared to invasive main-duct intraductal papillary mucinous neoplasm.
Ceppa EP; Roch AM; Cioffi JL; Sharma N; Easler JJ; DeWitt JM; House MG; Zyromski NJ; Nakeeb A; Schmidt CM
Surgery; 2015 Oct; 158(4):937-44; discussion 944-5. PubMed ID: 26173683
[TBL] [Abstract][Full Text] [Related]
6. Treatment strategy for main duct intraductal papillary mucinous neoplasms of the pancreas based on the assessment of recurrence in the remnant pancreas after resection: a retrospective review.
Tamura K; Ohtsuka T; Ideno N; Aso T; Shindo K; Aishima S; Ohuchida K; Takahata S; Ushijima Y; Ito T; Oda Y; Mizumoto K; Tanaka M
Ann Surg; 2014 Feb; 259(2):360-8. PubMed ID: 23989056
[TBL] [Abstract][Full Text] [Related]
7. Main duct and mixed type intraductal papillary mucinous neoplasms without enhancing mural nodules: Duct diameter of less than 10 mm and segmental dilatation of main pancreatic duct are findings support surveillance rather than immediate surgery.
Kim TH; Song TJ; Lee SO; Park CH; Moon JH; Pih GY; Oh DW; Woo SM; Yang YJ; Kim MH
Pancreatology; 2019 Dec; 19(8):1054-1060. PubMed ID: 31611130
[TBL] [Abstract][Full Text] [Related]
8. Predictive Factors for the Metachronous Development of High-risk Lesions in the Remnant Pancreas After Partial Pancreatectomy for Intraductal Papillary Mucinous Neoplasm.
Miyasaka Y; Ohtsuka T; Tamura K; Mori Y; Shindo K; Yamada D; Takahata S; Ishigami K; Ito T; Tokunaga S; Oda Y; Mizumoto K; Nakamura M; Tanaka M
Ann Surg; 2016 Jun; 263(6):1180-7. PubMed ID: 26334637
[TBL] [Abstract][Full Text] [Related]
9. Intraductal papillary mucinous neoplasms of the pancreas: an updated experience.
Sohn TA; Yeo CJ; Cameron JL; Hruban RH; Fukushima N; Campbell KA; Lillemoe KD
Ann Surg; 2004 Jun; 239(6):788-97; discussion 797-9. PubMed ID: 15166958
[TBL] [Abstract][Full Text] [Related]
10. Oncocytic-type intraductal papillary mucinous neoplasms: a unique malignant pancreatic tumor with good long-term prognosis.
Marchegiani G; Mino-Kenudson M; Ferrone CR; Warshaw AL; Lillemoe KD; Fernández-del Castillo C
J Am Coll Surg; 2015 May; 220(5):839-44. PubMed ID: 25840549
[TBL] [Abstract][Full Text] [Related]
11. Should non-invasive diffuse main-duct intraductal papillary mucinous neoplasms be treated with total pancreatectomy?
Blair AB; Beckman RM; Habib JR; Griffin JF; Lafaro K; Burkhart RA; Burns W; Weiss MJ; Cameron JL; Wolfgang CL; He J
HPB (Oxford); 2022 May; 24(5):645-653. PubMed ID: 34610896
[TBL] [Abstract][Full Text] [Related]
12. Malignant potential and specific characteristics of pure main duct type intraductal papillary mucinous neoplasm.
Fujita Y; Hirono S; Kawai M; Okada KI; Miyazawa M; Kitahata Y; Ueno M; Hayami S; Kobayashi R; Yanagisawa A; Yamaue H
Eur J Surg Oncol; 2022 May; 48(5):1054-1061. PubMed ID: 34933794
[TBL] [Abstract][Full Text] [Related]
13. Surgical strategy for intraductal papillary mucinous neoplasms of the pancreas.
Hirono S; Yamaue H
Surg Today; 2020 Jan; 50(1):50-55. PubMed ID: 31807871
[TBL] [Abstract][Full Text] [Related]
14. Histopathological evaluation of resected intraductal papillary mucinous neoplasms reveals distinct patterns of invasion in associated carcinomas.
Rift CV; Lund EL; Scheie D; Hansen CP; Hasselby JP
Hum Pathol; 2021 Jul; 113():47-58. PubMed ID: 33915115
[TBL] [Abstract][Full Text] [Related]
15. Long-term Risk of Pancreatic Malignancy in Patients With Branch Duct Intraductal Papillary Mucinous Neoplasm in a Referral Center.
Pergolini I; Sahora K; Ferrone CR; Morales-Oyarvide V; Wolpin BM; Mucci LA; Brugge WR; Mino-Kenudson M; Patino M; Sahani DV; Warshaw AL; Lillemoe KD; Fernández-Del Castillo C
Gastroenterology; 2017 Nov; 153(5):1284-1294.e1. PubMed ID: 28739282
[TBL] [Abstract][Full Text] [Related]
16. Patterns of recurrence and long-term outcomes in patients who underwent pancreatectomy for intraductal papillary mucinous neoplasms with high grade dysplasia: implications for surveillance and future management guidelines.
Blackham AU; Doepker MP; Centeno BA; Springett G; Pimiento JM; Malafa M; Hodul PJ
HPB (Oxford); 2017 Jul; 19(7):603-610. PubMed ID: 28495434
[TBL] [Abstract][Full Text] [Related]
17. Pancreatic main-duct involvement in branch-duct IPMNs: an underestimated risk.
Fritz S; Klauss M; Bergmann F; Strobel O; Schneider L; Werner J; Hackert T; Büchler MW
Ann Surg; 2014 Nov; 260(5):848-55; discussion 855-6. PubMed ID: 25379856
[TBL] [Abstract][Full Text] [Related]
18. Fate of Patients With Intraductal Papillary Mucinous Neoplasms of Pancreas After Resection According to the Pathology and Margin Status: Continuously Increasing Risk of Recurrence Even After Curative Resection Suggesting Necessity of Lifetime Surveillance.
Kim HS; Han Y; Kang JS; Choi YJ; Byun Y; Kim H; Lee KB; Kim H; Kwon W; Jang JY
Ann Surg; 2022 Oct; 276(4):e231-e238. PubMed ID: 32941274
[TBL] [Abstract][Full Text] [Related]
19. "Trivial" Cysts Redefine the Risk of Cancer in Presumed Branch-Duct Intraductal Papillary Mucinous Neoplasms of the Pancreas: A Potential Target for Follow-Up Discontinuation?
Marchegiani G; Andrianello S; Pollini T; Caravati A; Biancotto M; Secchettin E; Bonamini D; Malleo G; Bassi C; Salvia R
Am J Gastroenterol; 2019 Oct; 114(10):1678-1684. PubMed ID: 31449158
[TBL] [Abstract][Full Text] [Related]
20. Not all mixed-type intraductal papillary mucinous neoplasms behave like main-duct lesions: implications of minimal involvement of the main pancreatic duct.
Sahora K; Fernández-del Castillo C; Dong F; Marchegiani G; Thayer SP; Ferrone CR; Sahani DV; Brugge WR; Warshaw AL; Lillemoe KD; Mino-Kenudson M
Surgery; 2014 Sep; 156(3):611-21. PubMed ID: 25081232
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
